Articles tagged with Memory T Cells
Researchers identified central memory T cells as multipotent and self-renewing, generating diverse types of offspring to fight infections. This discovery has implications for clinical cell therapy and may improve the efficacy of immune-based treatments for cancers and other diseases.
A new Cornell University study reveals that infants' immune systems respond quickly to infection but struggle to create long-lasting immunity, leaving them vulnerable to illnesses. Researchers hope to design more effective vaccines and therapeutic interventions using this knowledge.
Scientists at UC San Diego School of Medicine have made a breakthrough discovery on the fate determination of T lymphocytes during an infection. They found that individual cells can make decisions about whether to become effector or memory cells almost immediately after exposure to a pathogen, suggesting that this process could be cruc...
Researchers found that memory T cells play a crucial role in lung transplant acceptance, suggesting that current immune-suppression strategies may contribute to organ rejection. The study aims to develop new strategies to selectively target immunosuppression in lung transplants and boost the ability of memory T cells.
A recent study identified a population of stem-like T memory cells where HIV persists despite treatment. These cells have the ability to regenerate new HIV-infected cells, fueling the virus's persistence in the human body. The findings suggest that targeting these cells could lead to novel interventions for future treatment.
A study published in Nature Immunology has identified two key proteins, KLF2 and S1P1, that influence immune response strategies. The findings suggest that cytokines play a major role in determining whether lymphocytes become resident memory cells or recirculate.
A phase II study tested thymoglobulin, an antithymocyte globulin treatment, in new-onset type 1 diabetic patients. While most younger patients showed decline in beta cell function, older patients experienced little change. The study did not meet its primary endpoint and may have identified biomarkers for safety and efficacy.
Joshua Obar has been honored with the ICAAC Young Investigator Award for his groundbreaking research on immunological memory responses. His work focuses on understanding how latent viral infections affect CD8 T cells and the formation of immune memories.
Researchers at National Jewish Health discovered that alum, a common vaccine adjuvant, works by coating with host DNA, inducing T cells to interact longer with the vaccine, resulting in a stronger immune response. This breakthrough could lead to more effective vaccines and improved public health outcomes.
Scientists chart individual T cells' fates to better understand immune response modeling and manipulation. They found that a sample of at least 50 individual cells is needed to generate a predictable immune response.
Researchers at Fred Hutchinson Cancer Center successfully infused large numbers of donor T-cells specific for the Wilm's Tumor Antigen 1 (WT1) to prolong survival in high-risk leukemia patients. The treatment showed improved anti-leukemic activity and reduced graft-vs.-host-disease.
Researchers at George Mason University have made a significant breakthrough in understanding how the HIV virus targets 'veteran' memory T-cells. By exploiting the cell's treadmilling process, the virus can infect and kill these cells, leaving the body vulnerable to disease.
Researchers at Albert Einstein College of Medicine discovered a new 'first response' mechanism that the immune system uses to respond to infection, challenging current understanding of immunity. This fast-acting immune response is orchestrated by inflammatory monocytes and can provide immediate protection against microbes.
Researchers found that miR-122 modulates fat and cholesterol metabolism and has a tumor suppressive function in hepatocytes. A mouse model with MiR-122 loss of function also promoted breast tumor growth by differentially regulating ERα and ERβ.
A new study found that the number of viruses involved in a flu infection impacts the immune response, with high-dose infections generating stronger immunity and increased protection against reinfection. This discovery could lead to improved vaccine design and broader protection against emerging flu strains.
A study published in the Journal of Experimental Medicine suggests that replacing naive CD4+ T cells with memory CD4+ T cells may be a more effective approach to combating HIV. The loss of naive T cells had no effect on the maintenance of memory CD4+ T cells, whose loss proceeded similarly with or without naive cell replacements.
A recent study published in the Journal of Experimental Medicine found that humans can build up memory T cell numbers over time without sacrificing old ones, unlike previous studies on mice that suggested space limitations. The discovery has significant implications for understanding human immune responses and potential treatments.
Researchers at Brigham and Women's Hospital discovered memory T cells living in skin that protect against infection and disease. These resident cells are more important for immunity than previously thought and suggest a fundamental shift in how vaccines are designed and delivered.
Researchers at Arizona State University investigate the coordination of a particular type of immune response involving the release of IFN-λ, a cell-signaling protein molecule. They found that antigen-independent production of IFN-λ by memory T cells relies on splenic dendritic cells and NOD-like receptors.
Researchers at the La Jolla Institute identified a previously unknown mechanism generating protective immune memory cells to fight recurring infections at mucosal linings. This discovery could lead to the creation of new and more effective vaccines by triggering the newly identified mechanism, particularly for Listeria and HIV.
Researchers at Brigham and Women's Hospital are studying the role of tissue resident T cells in fighting viral, fungal, and bacterial infections, as well as certain cancers. The study aims to develop vaccines that generate long-lived populations of protective memory T cells.
Researchers identified a new type of T cell that can produce acetylcholine, a neurotransmitter that blocks inflammation. This discovery suggests a novel approach to treating inflammatory and autoimmune diseases by targeting the nerves and T cells.
Memory T cells that initially developed against a virus upon first encounter can be lost during chronic infections, making it challenging for vaccine development. Researchers at the Emory Vaccine Center have identified a molecule called 2B4 on memory cells that slows them down during chronic infections.
Researchers have discovered that innate immune cells can form a type of 'memory' that protects against viral infections. This finding has significant implications for the design of future vaccines, particularly for HIV. The study found that natural killer cells can recognize and respond to viruses more effectively after previous exposure.
Researchers have discovered a way sooty mangabeys' immune cells resist SIV infection: they close the gates that viruses use to enter cells. This finding may lead to better coping strategies for HIV-infected individuals.
Scientists have discovered a molecule that determines which T cells become memory cells just days after a viral infection starts. This finding could lead to more effective vaccines for diseases like HIV/AIDS and cancer.
Researchers at Sanford-Burnham Medical Research Institute have identified a new function of the CD44 receptor, which helps specific T helper cells develop immunologic memory. This discovery could lead to the development of therapies to control disease pathology in various infections and autoimmune conditions.
Dr. Masopust's work on immunological memory of bacterial and viral pathogens has transformed the field of memory T cell biology. His research demonstrated functional differences between lymphoid and non-lymphoid CD8 memory T cells.
Researchers at The Wistar Institute have identified a protein called Blimp-1 that can help reprogram exhausted immune cells into more effective 'soldiers' against certain viruses and cancers. By understanding how Blimp-1 suppresses normal immune responses, scientists may develop new strategies to prevent and treat chronic infections.
Researchers at Emory Transplant Center developed a combination therapy that replaces calcineurin inhibitors with costimulation blockers and alefacept, reducing rejection rates in monkey transplants. The new regimen allows for less-toxic post-transplant treatment, potentially administered once a week.
Scientists discovered rapamycin's paradoxical effect on immune cells, stimulating memory CD8 T cells to respond faster and stronger to infections. This finding may lead to developing new vaccines with drugs similar to rapamycin.
Researchers at the University of Pennsylvania School of Medicine have found that metformin can enhance the effectiveness of vaccines by boosting numbers of cancer-fighting T cells. This resulted in a larger population of memory immune cells that were able to fight off a tumor at a later time.
Identifying a transcription factor that regulates blood stem cells, researchers found ELF4 activates an inhibitor that stops naive T cells from proliferating. This discovery could lead to better vaccines and more effective cancer immunotherapy by controlling T cell growth and production.
Researchers have decoded the language of memory cells that protect against re-infection, a breakthrough in understanding immunological memory development. The study reveals distinct program generates memory cells for vaccine effectiveness and cancer research applications.
UT Southwestern researchers found that interferon and another signaling protein are needed to create memory cells that remember how to fight off the virus. Without these cells, the body is defenseless against re-infections.
Researchers discover HIV's ability to break down the internal skeleton of resting T cells, allowing it to overcome a previously resistant barrier. This process involves the activation of protein cofilin and actin microfilaments, which may provide a new target for therapy.
A recent study published in PLOS Pathogens found that T cell proliferation is delayed by up to three days after infection, which may provide an evolutionary safeguard against autoimmune responses. This delay allows the immune system's front-line innate response to quickly control the infection before memory cell division takes place in...
New study reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity in mice. Administering IL-7 during the immune response contraction phase improves viral control and boosts vaccine-induced CD8+ T cell memory.
Researchers at the University of Wisconsin-Madison found that administering interleukin-7 during a specific stage of infection can increase the number of killer cells capable of destroying virus-infected cells, enhancing immune memory. This discovery may lead to improved vaccine efficacy against HIV and cancer.
Researchers at Karolinska Institute have identified a new source of dopamine cells that provided marked benefit when transplanted into mice with Parkinson's-like disease. Wnt5a-treated neural stem cells may be an efficient and safe source for DA cell replacement therapy in individuals with PD.
Researchers at Fox Chase Cancer Center discovered that memory CD8 T cells can protect against viral diseases without migrating to the site of infection. These cells rapidly multiply and kill target cells inside the lymph node, decreasing viral spread to vital organs.
Scientists at The Wistar Institute found that CD8 T cells generated to fight chronic infections operate under a different maintenance scheme than those in acute infections. These cells have a rapid turnover and are dependent on the virus for their continuation, which could be manipulated to design new therapeutic options.
A new study suggests that artificial stimulation of CD28 on memory T cells can cause severe organ damage. Researchers found that activated memory T cells migrate to organs where there is no infection, leading to significant tissue harm.
A study published in PLoS Medicine found that HIV treatment does not restore memory T cells in most people, despite years of antiviral therapy. The researchers discovered that intestinal immune cells remained low and elevated immune activation persisted, suggesting potential clinical problems over time.
Researchers found that HIV-1 infection leads to the loss of immune cells in the gut, which may never return to normal levels. A subset of patients showed only half the normal number of CD4+ effector memory T cells in their GI tracts despite effective antiretroviral therapy.
A team of researchers identified a protein, Lck, that plays a crucial role in stimulating immune cells to recall past encounters with pathogens, enabling quick responses to reinfection. This discovery may aid in the development of vaccines against diseases like AIDS and autoimmune disorders.
A new study suggests that post-transplant lymphoproliferative disorder (PTLD) arises when immune cells called scout cells become weakened, allowing the Epstein-Barr virus to cause cancer. The study identifies a mechanism that may explain why some patients develop PTLD and others don't.
Researchers found that monkeys vaccinated against simian immunodeficiency virus (SIV) survived longer after infection compared to unvaccinated animals. The vaccine regimen preserved memory CD4+ T cells, enabling the animals to live healthier lives.
Researchers reveal that specific physical and chemical cues guide CD8+ T cells to sites of activation in the lymph node. This discovery provides insight into the fundamental behavior of the immune system and suggests new approaches to vaccine strategies.
Researchers at Scripps Research Institute found that injecting cytokine-antibody complexes stimulates a massive selective increase in T cell response. The study suggests these complexes could be clinically useful for selectively boosting or inhibiting immune responses in vivo, potentially treating autoimmune disease and cancer.
The study found that T cells recognize brain proteins and recruit resident immune cells to fight off toxic substances, enabling neurogenic regions like the hippocampus to form new nerve cells. This process is linked to local immune activity and may play a role in maintaining learning and memory abilities in adulthood.
Researchers at the University of Iowa have discovered a new vaccination strategy that dramatically speeds up the immunization process by greatly reducing the required 'lag time' between initial vaccination and booster shots. This finding has important implications for immunotherapy, where developing immunity fast is critical.
T cells activated during IBD found in PSC livers, re-routed by aberrant attractant protein. Long-lived memory cells may explain delayed liver disease onset after IBD resolution.
Research by Emory University scientists found that chronic viral infections fail to develop long-term immune memory cells due to poor cytokine response. The study suggests that rest from antigen exposure is crucial for developing these memory cells.
Scientists have created a genetically modified parasite to study the immune system's memory, which could aid in developing vaccines for Leishmania major, AIDS, and tuberculosis. Researchers found that central memory T cells remain primed to fight new infections even after initial infection has cleared.
Scientists have found a new form of long-term memory T cell that can combat leishmaniasis even without the parasite's presence. This discovery may lead to an effective vaccine against this disease and others mediated by immune cells.
Researchers found that activation of Serine protease inhibitor 2A (Spi2A) can prevent T cell death and increase memory T cells, potentially boosting vaccine efficacy. This discovery could lead to new vaccines or treatments for chronic infections and autoimmune diseases.
Researchers at Yale University demonstrate that OspC is critical for Borrelia burgdorferi's ability to invade tick salivary glands and be transmitted to humans. Meanwhile, studies on hereditary spastic paraplegia and idiopathic pulmonary fibrosis reveal potential new targets for treatment.
A phase 3 clinical trial found that alefacept reduced CD4+ and CD8+ memory T cell counts, leading to improved psoriasis symptoms. The treatment's benefits lasted longest in patients with the greatest reduction in T cell counts.
Researchers found a marker for long-term immunity in CD8 T cells using the interleukin 7 (IL-7) receptor. This discovery can help scientists create more effective vaccines and develop new treatments for chronic viral infections and cancer.